Setting specifications for non-normally distributed data.

H Saranadasa

doi:10.1081/bip-100101015

Home/Archive/PubMed

PubMed · 10709803

Setting specifications for non-normally distributed data.

H Saranadasa

View original source ↗Export metadata ↓

Abstract

In this paper, we focus on estimating an upper specification for non-normally distributed data. Cornish-Fisher expansions were exploited for derivations of the method. The method was applied for upper specification calculations of two particle-size data sets, and simulation studies were also performed to demonstrate the accuracy of the approximations. The method was also used to calculate the critical values for delta(min) for the Anderson-Hauck test for equivalence using bootstrap samplings. The main advantage of the method is in calculating specifications with limited data.

Explore related subjects

Chemistry, Pharmaceutical Computer Simulation Monte Carlo Method Particle Size Statistical Distributions Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H Saranadasa. 2000. Setting specifications for non-normally distributed data.. https://doi.org/10.1081/bip-100101015

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Alternative statistical parameter for high-throughput screening assay quality assessment.

High-throughput screening is an essential process in drug discovery. The ability to identify true active compounds depends on the high quality of assays and proper analysis of data. The Z factor, presented by Zhang et al. in 1999, provides an easy and useful summary of assay quality and has been a widely accepted standard. However, as data analysis has undergone much improvement recently, the assessment of assay quality has not evolved in parallel. In this article, the authors study the implications of Z factor values under different conditions and link the Z factor with the power of discovering true active compounds. They discuss the different interpretations of Z factor depending on error distributions and advocate direct analysis of power as assay quality assessment. They also propose that in estimating assay quality parameters, adjustments in data analysis should be taken into account. Studying the power of identifying true "hits" gives a more direct interpretation of assay quality and may provide guidance in assay optimization on some occasions.

Chemistry, Pharmaceutical↗

PubMed2007

Nonaqueous capillary electrophoresis in pharmaceutical analysis.

This review presents different solvents and electrolytes commonly used as BGEs in NACE for the analysis of pharmaceutical compounds. Most NACE applications carried out since 1998 for the analysis of compounds of pharmaceutical interest are presented in four tables: (i) analysis of drugs and related substances, (ii) analysis of chiral substances, (iii) analysis of phytochemical extracts and (iv) analysis of drugs in biological fluids. These selected examples are used to illustrate the interest in NACE versus conventional aqueous CE.

Chemistry, Pharmaceutical↗

PubMed2007

Recent progress in capillary ITP.

ITP has been attracting constant attention for many years due to its principal capability to concentrate trace analytes by several orders of magnitude. In the current capillary format, it is able to concentrate trace analytes diluted to several microliters of an original sample into concentrated zones having volumes in the range of picoliters. Due to this reason, ITP holds an important position in many current multistage and multidimensional separation schemes. This article links up previous reviews on the topic and summarizes the progress of analytical capillary ITP since 2002. Almost 100 papers are reviewed that include methodological novelties, instrumental aspects, and analytical applications. Papers using ITP and/or isotachophoretic principles as part of multistage and/or multidimensional separation schemes are also included.

Chemistry, Pharmaceutical↗